Kezar Life Sciences Inc. (KZR)

NASDAQ: KZR · Real-Time Price · USD

4.43

0.03 (0.68%)

At close: May 02, 2025, 11:50 AM

Kezar Life Sciences Revenue

Kezar Life Sciences reported an annual revenue of $0, reflecting a -100% growth. For the quarter ending December 31, 2024, Kezar Life Sciences generated $0 in revenue.

Revenue (ttm)

Revenue Growth

-100%

Price / Sales Ratio

Revenue / Employee

Employees

Market Cap

32.36M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	% Change

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company	Revenue
Kymera Therapeutics	47.07M
Nurix Therapeutics	54.55M
Keros Therapeutics	3.55M
Stoke Therapeutics	36.55M
Monte Rosa Therapeutics	75.62M

Revenue Rankings

KZR News

38 days ago - Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript) - seekingalpha.com
38 days ago - Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - businesswire.com
39 days ago - Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - businesswire.com